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Objective: In this population-based study, we aimed to determine whether neuropsychiatric 
history, medication or family history of neuropsychiatric disorders predicted cognitive and/or 
behavioural impairment in motor neurone disease (MND). 
 
Methods: People with MND (pwMND) on the Scottish CARE-MND register, diagnosed 
from January 2015-January 2018, with cognitive and/or behavioural data measured using the 
Edinburgh Cognitive and Behavioural ALS Screen (ECAS) were included. Data was 
extracted on patient neuropsychiatric, medication and family history of neuropsychiatric 
disorders.  
 
We identified patients with cognitive (MNDci, MNDcbi or MND-FTD) and behavioural 
(MNDbi, MNDcbi or MND-FTD) impairment.  
 
Results: Data were available for 305 pwMND (mean age at diagnosis=62.26 years, 
SD=11.40), of which 60 (19.7%) had a neuropsychiatric disorder. A family history of 
neuropsychiatric disorders was present in 36/231 (15.58%) of patients.  
 
Patient premorbid mood disorders were associated with increased apathy (OR=2.78, 
95%CI=1.083 to 7.169). A family history of any neuropsychiatric disorder was associated 
with poorer visuospatial scores, MNDbi (OR=3.14, 95%CI=1.09 to 8.99) and MND-FTD 
(OR=5.08, 95%CI=1.26 to 20.40). A family history of mood disorders was associated with 
poorer overall cognition (exp(b)=0.725, p=0.026), language, verbal fluency and visuospatial 
scores, and MND-FTD (OR=7.57, 95%CI=1.55 to 46.87). A family history of neurotic 
disorders was associated with poorer language (exp(b)=0.362, p<0.001), visuospatial scores 
(exp(b)=0.625, p<0.009) and MND-FTD (OR=13.75, 95%CI=1.71 to 110.86). 
 
Conclusions: Neuropsychiatric disorders in patients and their families are associated with 
cognitive and behavioural changes post-MND diagnosis, with many occurring independently 
of MND-FTD and C9orf72 status. These findings support an overlap between MND, FTD 
and neuropsychiatric disorders, particularly mood disorders. 
Up to 50% of people with amyotrophic lateral sclerosis (ALS), the most common form of 
motor neurone disease (MND), experience cognitive and/or behaviour changes, with 15% 
meeting the criteria for frontotemporal dementia (FTD).1, 2 These changes represent a range 
of frontotemporal spectrum disorders in ALS (ALS-FTSD).3 A genetic and pathological 
overlap between MND and FTD has been established with the C9orf72 repeat expansion 
occurring in ~6.3% of sporadic ALS cases, ~5.8% of sporadic FTD cases4 and ~33% of 
familial MND cases,5 and the TAR-DNA-binding protein 43 (TDP-43) occurring in almost 
all ALS, ALS-FTD and ~45% FTD cases.6-8  
 
Cognitive and behavioural symptoms in MND range from no impairment to cognitive 
impairment (ALSci), behavioural impairment (ALSbi), both (ALScbi) or ALS-FTD.3 An 
association between neuropsychiatric disorders and ALS has previously been shown.9, 10 
Neuropsychiatric symptoms including schizophrenia, depression, anxiety and drug abuse or 
dependence are common in the years prior-to and following diagnosis in both ALS10, 11 and 
behavioural variant FTD.12 Genome wide association studies (GWAS) have revealed a 
modest genetic correlation between schizophrenia and ALS.13 Furthermore, higher rates of 
psychosis, suicidal behaviour 14 and autism15 have been shown in ALS patients’ first and 
second-degree relatives,14, 15 particularly in their children.11 Despite evidence of an overlap of 
ALS-FTSD and neuropsychiatric disorders, it is unclear if neuropsychiatric disorders also 
contribute to the spectrum of cognitive and behavioural changes in ALS. 
 
Using population-based data from the Scottish Clinical, Audit, Research and Evaluation of 
MND (CARE-MND) register, this study aimed to look at the association between cognitive 
and/or behavioural changes in MND as measured using the Edinburgh Cognitive and 
Behavioural ALS Screen (ECAS)16 and neuropsychiatric disorders in MND kindreds’. 
Specifically, we aimed to determine if the presence of cognitive and behaviour changes can 
be predicted by the patient’s: 
1. History of neuropsychiatric disorders 
2. History of neuropsychiatric medication 
3. Family history of neuropsychiatric disorders. 
METHODS 
Participants: 
We studied people with MND (pwMND) registered on the CARE-MND platform, a 
population-based, prospective database of patients in Scotland diagnosed with MND.17, 18 
Since 2015, a major update of the register has taken place. Ethical approval was obtained for 
the original (MREC/98/0/56 1989-2010, 10/MRE00/78 2011-2015) and updated CARE-
MND platform (Scotland A Research Ethics Committee, 15/SS/0126). Anonymised data for 
collaboration can be obtained upon reasonable request from the CARE-MND register. In 
Scotland, any patient receiving a diagnosis of MND (including ALS, and subtypes such as 
primary lateral sclerosis (PLS), progressive muscular atrophy (PMA) and progressive bulbar 
palsy (PBP)) is included on the register. pwMND can consent for their anonymised 
information to be used for research purposes. This study includes all consenting patients 
diagnosed with MND (240 ALS, 23 PLS, 9 PMA and 23 ALS-FTD) between January 2015 
to January 2018 with ECAS data available.  
 
Measures: 
History of neuropsychiatric disorders 
Neuropsychiatric history in patients:  
We identified patients with a history of neuropsychiatric disorder (pre- or post-MND 
diagnosis) from data on the CARE-MND register, using medical history information. We 
assessed each patient on a case-by-case basis, and identified any relevant neuropsychiatric 
diagnoses (Table 1). Each diagnosis was then categorised based on the International 
Classification of Diseases–10 (ICD-10). 19 We created a summary variable to indicate 
(yes/no) the presence of a relevant neuropsychiatric diagnosis for each individual.  
 
Table 1. Neuropsychiatric disorders of MND patients on the CARE-MND register. 
 
ICD 10 Classification Neuropsychiatric disorder reported on CARE-MND Register 
Mood [affective] disorder 
F30-F39 
Depression 
Low mood 
Neurotic (reactive) depression 
Mania 
Neurotic, stress-related and 
somatoform disorders 
F40-F48 
Anxiety 
Claustrophobia 
Obsessive compulsive disorder 
Post-traumatic stress disorder 
Panic attacks 
Mental and behavioural disorders 
due to psychoactive substance use 
F10-F19 
Personal history of psychoactive substance abuse 
Benzodiazepine dependence 
Alcohol excess 
Alcohol abuse 
Referral alcoholic 
Alcohol dependence syndrome 
Schizophrenia, schizotypal and 
delusional disorders 
F20-F29 
Affective psychoses 
Visual hallucinations 
Disorders of adult personality and 
behaviour 
F60-F69 
Personality disorder 
Intentional self-harm 
X60-X84 
Suicide + self-inflicted poisoning by solvents 
 
Neuropsychiatric medication history in patients:  
We assessed each patient’s medication history (pre- and post-MND diagnosis) to identify any 
relevant neuropsychiatric medication (supplementary eTable 1). We excluded medication 
typically used to treat the symptoms of MND (e.g. lorazepam) and cases where alternative or 
secondary use of the medication were stated (e.g. muscle cramps). We created a summary 
variable to indicate (yes/no) the presence of a relevant neuropsychiatric medication for each 
individual.  
 
Family history of neuropsychiatric disorders: 
Information on a family history of neuropsychiatric disorders (pre-MND diagnosis) was 
available on the CARE-MND register. These data were collected during routine clinical 
assessment around the time of MND diagnosis using a standardised proforma. Patients 
provided information on any family history of MND, dementia, neurological or 
neuropsychiatric disorders across four generations of blood relatives (patient’s grandparents 
to children). We defined a positive family history as one or more relatives with a diagnosed 
neuropsychiatric disorder. 
 
Cognition and Behaviour  
ECAS cognitive and behaviour scores 
Cognition and behaviour were measured using the ECAS.16 This brief assessment, 
specifically designed for patients with motor degeneration, is both sensitive and specific to 
the types of impairments shown by ALS patients20-23 and is routinely undertaken in Scotland. 
ECAS subscales are grouped into ALS specific domains (language, verbal fluency and 
executive functioning) and ALS non-specific domains (memory and visuospatial skills). A 
total score (max 136) and domain specific scores (ALS-Specific, max 100, ALS non-specific 
max 36) are calculated with established cut-offs indicating global and domain-specific 
impairment. The ECAS has been shown to be a sensitive and valid measure of cognition and 
behaviour in MND16, 20 with good convergent validity with other screening tests.21-24 
 
The ECAS behavioural interview was used to assess behaviour change across five domains 
based on behavioural-variant FTD diagnostic criteria:25 disinhibition; apathy or inertia; loss 
of sympathy/empathy; perseveration and eating behaviour/hyperorality. The interview was 
completed by an informant, with a score of one indicating a behaviour change for that 
domain, with a maximum of five denoting the number of behavioural domains affected.  
 
MND-FTSD subclasses 
Using all available cognitive and behavioural data, we classified patients using the ALS-
FTSD criteria.3 We used published cut-offs for the ECAS total and ALS-specific scores16 
which have been shown to have maximum sensitivity and specificity to detect cognitive 
impairment against extensive gold standard neuropsychological assessment.20 As we included 
all MND subtypes, we referred to these subclasses as MND-FTSD. Using this method, we 
identified those with cognitive (MNDci), behavioural (MNDbi) or both cognitive and 
behavioural impairment (MNDcbi). Cases of MND-FTD were identified on the CARE-MND 
register based on a diagnosis given by a neurologist during clinical examination.  
 
The number of patients in some MND-FTSD subclasses was small for some analyses. To 
increase power, we collapsed the categories to identify patients with any type of cognitive 
(MNDci, MNDcbi and MND-FTD) or behavioural (MNDbi, MNDcbi, MND-FTD) 
impairment.  
 
Patients recruited to the CARE-MND register donated blood or saliva for genetic analysis. 
C9orf72 genotyping was carried out using polymerase chain reaction (PCR) based on 
methods previously described.26 
 
Statistical Analysis: 
Some participants had multiple ECAS scores available from repeat testing (n=39, max=3 
entries). We included entries with the most complete data (n=23) and where the date of 
assessment was available (n=2). In cases where there were two entries within 6 months of 
each other (n=5), we used the first assessment to avoid potential practice effects.27, 28 We 
examined predictors of cognitive and behavioural change in MND and given that these may 
increase during later stages of the disease,29 we used the most recent ECAS entry for the 
remaining cases (n=9). 
 
Dates of neuropsychiatric diagnosis and prescription of medication were available for some, 
but not all patients on the CARE-MND register. We focussed our analyses on all identified 
cases to increase statistical power. In addition, we conducted secondary analyses examining 
only those with confirmed premorbid information based on date of diagnosis or prescription 
of medication.  
 
We examined the relationships between neuropsychiatric disorders, medication and family 
history and two outcomes: A) continuous cognitive and categorical (yes/no) behavioural 
ECAS scores and B) MND-FTSD subclasses, including the presence of any cognitive or 
behavioural impairment. The use of continuous scores increased statistical power to detect 
effects. However, the use of MND-FTSD subclasses to identify predictors of cognitive and/or 
behavioural impairments has important clinical implications. For analyses using continuous 
outcomes, we used linear regression and reverse log transformed ECAS scores where 
appropriate to avoid violation of normality. Results were back transformed for reporting. We 
examined the presence of each behaviour change using a series of binomial logistic 
regressions and MND-FTSD subclass using multinomial regression. For collapsed MND-
FTSD subclasses indicating the presence of any cognitive or behaviour impairment, we used 
binomial logistic regression. Where appropriate, sensitivity analyses were conducted to 
determine if the associations were driven by MND-FTD cases and whether they remained 
after controlling for C9orf72 status. All analysis was conducted in R30 and power calculations 
were conducted using the pwr package.31 
 RESULTS 
Information was available for 305 pwMND with ECAS data (mean age at diagnosis=62.26 
years, SD=11.40, Table 2). 211 (69.2%) had complete cognitive and behavioural data, 82 
(26.9%) had some cognition only and 12 (3.9%) had behavioural data only. C9orf72 status 
was available in 259 (84.9%) patients, of which 24 (9.3%) carried disease causing 
expansions.  
 
Total ECAS scores (n=292, unavailable for one case) ranged from 24 to 132 out of 136 
(mean=104.74, SD=18.48) and apathy was the most common behaviour change (68/229, 
29.7%, see Figure 1 for frequencies of impairment). A MND-FTSD syndrome was found in 
156 (51.1%): MNDci was present in 77 (25.2%), MNDbi in 33 (10.8%) and MNDcbi in 29 
(9.5%) patients. MND-FTD was identified in 17 (5.6%) patients based on a neurologist’s 
diagnosis. The remaining 149 (48.9%) patients did not fulfil criterion for cognitive and/or 
behavioural impairment however, 18 patients were impaired on the ALS non-specific but not 
the ALS specific subscales. There were no significant differences between those with and 
without any impairment on demographic or clinical characteristics.  
 
Table 2. Descriptive statistics of MND patients on the CARE-MND register with ECAS data 
(n=305). 
 
Demographic Mean/Frequency 
Age at symptom onseta 60.56±11.45 
Age at diagnosis 62.26±11.40 
Sex: Male  202 (66.2%) 
Handedness:  
 
     Right 232 (89.9%) 
     Left 23 (8.9%) 
     Both 3 (1.2%) 
Diagnosis: 
 
     ALS/MND 240 (78.7%) 
     ALS/MND-FTD 17 (5.6%) 
     PLS 23 (7.5%) 
     PMA 9 (2.0%) 
     Other/unknown 16 (5.2%) 
C9orf72 Status  
     C9+ 24 (7.9%) 
     C9- 235 (77.0%) 
     Not tested 46 (15.1%) 
Disease duration at time of 
ECAS (days)b 
411.16±770.94 
Deceased 178 (58.4%) 
± Mean and standard deviation 
a Patient self-report of motor symptoms 
b Number of days between diagnosis and ECAS testing (n=294). 
 
The relationship between patients’ neuropsychiatric history and cognition and 
behaviour 
Of the 305 people with ECAS data on the CARE-MND register, 60 patients had a medical 
history of a neuropsychiatric disorder. Those with and without a neuropsychiatric disorder 
did not differ on C9orf72 status (x2=0.098, p=0.755), however those with a neuropsychiatric 
disorder had a shorter disease duration at the time of ECAS (median=81 days) than those 
without (median=177 days; W=8458, p=0.005). No relationship was found between disease 
duration and total ECAS, ALS specific or ALS non-specific scores.  
 
Mood disorders were the most common (n=42) followed by neurotic disorders (n=19), 
personality disorders (n=3), and schizophrenia, schizotypal and delusional disorder (n=1, 
Table 3). Based on diagnosis date, 39 had a definite premorbid neuropsychiatric disorder (2 
were diagnosed post-MND diagnosis, 19 missing date). Those with a premorbid 
neuropsychiatric disorder had a shorter disease duration at the time of ECAS compared those 
without (77 vs 177 days, W=5583.5, p=0.006). There were no other significant differences on 
demographic or disease characteristics. 
 
Table 3. Frequency of neuropsychiatric disorders in MND patients and their family members 
on the CARE-MND register. 
 
  MND Patients MND Family members 
n(%) 
All 
neuropsychiatric 
disorders 
(n=60)a 
Premorbid 
neuropsychiatric 
disorders (n=39)b 
Positive 
family history 
(n=36) 
Mood disorders  42 (70.00%) 28 (71.80%) 16 (44.44%) 
Neurotic disorders 19 (31.67%) 13 (33.33%) 9 (25.00%) 
Schizophrenia, schizotypal or 
delusional disorder 1 (1.67%) 0 (0.00%) 10 (27.80%) 
Disorders of adult personality 
and behaviour 3 (5.00%) 2 (5.13%) 0 (0.00%) 
Mental and behavioural 
disorders due to psychoactive 
substance use 
0 (0.00%) 0 (0.00%) 3 (8.30%) 
Intentional self-harm 0 (0.00%) 0 (0.00%) 3 (8.30%) 
NOTE: Percentages are based on the number of people with neuropsychiatric disorders on the 
CARE-MND register (see n in each header).   
a Includes all cases of neuropsychiatric disorder regardless of date of diagnosis.  
b Includes neuropsychiatric disorders with a date of diagnosis prior to MND diagnosis only.  
 
The analyses of ECAS scores revealed that a diagnosis of a mood disorder was associated 
with poorer language scores but no other specific subscale (Table 4). A diagnosis of any 
neuropsychiatric disorder was associated with increased likelihood of apathy but no other 
specific behavioural domain. Examination of each individual neuropsychiatric disorder 
showed an association between mood disorders and increased risk of apathy. We did not find 
any other significant associations between patient neuropsychiatric disorders and cognition or 
behaviour. After excluding MND-FTD cases, these associations were no longer significant. 
After controlling for C9orf72 status, the association between mood disorders and language 
scores was no longer significant however all other associations remained. 
Table 4. Depression and anxiety associations with ECAS cognitive and behaviour scores. 
 
 Neuropsychiatric disorders at any time point (n=60) 
 
Any neuropsychiatric 
disorder 
Mood Disorders Neurotic Disorders 
  exp(B) p exp(B) p exp(B) p 
Language 0.826 0.114 0.751 0.040 0.940 0.754 
Verbal Fluency 0.895 0.296 0.852 0.192 0.990 0.953 
Executive functioning 0.914 0.317 0.903 0.328 1.030 0.844 
ALS Specific 0.900 0.231 0.869 0.166 1.039 0.795 
Memory 0.938 0.400 0.914 0.308 0.858 0.229 
Visuospatial 0.950 0.525 0.962 0.676 1.015 0.908 
ALS Non-specific 0.943 0.459 0.925 0.398 0.885 0.352 
Total ECAS 0.910 0.231 0.882 0.168 0.990 0.939 
  OR 95%CI OR 95%CI OR  95%CI 
Disinhibition 1.177 0.650 to 4.370 1.621 0.507 to 4.393 0.975 0.051 to 5.642 
Apathy or inertia 2.055 1.020 to 4.097 2.565 1.178 to 5.573 1.950 0.470 to 7.598 
Loss of sympathy or empathy 1.257 0.545 to 2.719 1.409 0.555 to 3.280 1.105 0.161 to 4.758 
Perseveration 1.328 0.527 to 3.056 1.336 0.465 to 3.354 1.555 0.047 to 5.521 
Hyperorality or altered food preferences 1.047 0.397 to 2.462 0.998 0.319 to 2.604 1.510 0.219 to 6.562 
Results in bold indicate a significant association. 
 
In secondary analysis examining those with confirmed premorbid neuropsychiatric disorders 
only (n=39), the association between mood disorders and apathy remained (supplementary 
eTable 2). The associations between mood disorders and language scores and any 
neuropsychiatric disorder and apathy were no longer significant; however, in both cases, 
statistical power was low (0.34 and 0.16 respectively). 
 
The analyses of MND-FTSD classifications revealed that mood disorders were associated 
with increased odds of MNDbi vs MND with no impairment (Table 5). This association 
remained after excluding MND-FTD cases and controlling for C9orf72 status. We did not 
find any other associations (Table 5 and Figure 2a) including those examining premorbid 
cases only (supplementary eTable 3 and eFigure 1a). 
 
Table 5. Patient neuropsychiatric disorders and MND-FTSD subclasses. 
 
 Neuropsychiatric disorders at any time point (n=60) 
 
Any premorbid 
neuropsychiatric 
Mood Disorders Neurotic Disorders 
  OR 95% CI OR 95% CI OR 95% CI 
MND (ref) - - - - - - 
MND-FTD 2.067 0.669 to 6.387 3.219 0.916 to 11.312 2.074 0.410 to 10.502 
MNDbi 2.157 0.915 to 5.085 3.923 1.511 to 10.187 0.486 0.059 to 3.975 
MNDci 0.794 0.254 to 2.480 1.207 0.322 to 4.535 1.315 0.450 to 3.839 
MNDcbi 1.301 0.647 to 2.616 2.125 0.932 to 4.845 0.556 0.068 to 4.562 
Results in bold indicate a significant association.  
 
The relationship between patients’ history of neuropsychiatric medication and their 
cognition and behaviour 
Of the 305 patients with ECAS data on the CARE-MND register, 127 had a relevant 
neuropsychiatric medication in their medical history (92 antidepressants, 54 benzodiazepines 
and 5 antipsychotics). Based on date of medication prescription and date of MND diagnosis, 
25 people were identified with premorbid neuropsychiatric medication (57 were prescribed 
post-MND diagnosis and 45 missing dates). There were no significant differences between 
those with premorbid neuropsychiatric medication and those without on demographic or 
disease characteristics.  
 
We found no associations between the prescription of any neuropsychiatric medication and 
cognition and/or behaviour changes (supplementary eTable 4), MND-FTSD subclass 
(supplementary eTable 5) or behaviour or cognitive impairment (eFigure 2). All results 
remained non-significant when including only those with medication prescribed prior to 
MND diagnosis (supplementary eTable 6-7 and eFigure1b). 
 
The relationship between patients’ family history of neuropsychiatric disorders and 
their cognition and behaviour 
Of the 305 people with ECAS data on the CARE-MND register, information on family 
history of neuropsychiatric disorders was available for 231 (75.74%) patients. Patients with 
and without a family history of neuropsychiatric disorders did not differ on C9orf72 status 
(x2=3.209, p=0.073). A positive family history of any neuropsychiatric disorder was present 
in 36/231 (15.58%).  Mood disorders was the most common (n=16) followed by 
schizophrenia, schizotypal or delusional disorders (n=10) and neurotic disorders (n=9, Table 
3). A positive family history of dementia was reported in 76/266 (29%, data unavailable for 
39) as was associated with increased odds of a family history of neuropsychiatric disorders 
(OR=4.198, 95%CI=1.996 to 8.958). There were no other differences between those with and 
without a family history of neuropsychiatric disorders on demographic or disease 
characteristics.  
 
A family history of any neuropsychiatric disorders was associated with poorer visuospatial 
scores. A family history of mood disorder was significantly associated with poorer total 
ECAS and ALS non-specific scores, as well as poorer language, verbal fluency and 
visuospatial scores. For a family history of neurotic disorders, we found an association with 
poorer language and visuospatial scores (Table 6). We did not find any other significant 
associations between family neuropsychiatric disorders and cognition or behaviour. After 
excluding MND-FTD cases, the association between family history of neurotic disorders and 
language scores remained (exp(B)=0.463, p=0.013). All other associations were no longer 
significant. All associations remained after controlling for C9orf72 status.  
 
 
Table 6. Family history of neuropsychiatric disorders and cognitive and behavioural outcomes in patients. 
Results in bold indicate a significant association. 
* Remained statistically significant following Bonferroni-Holm correction for multiple comparisons. 
 
 
Any neuropsychiatric 
disorder 
Mood disorders Neurotic disorders 
Schizophrenia, 
schizotypal and 
delusional disorders 
  exp(B) p exp(B) p exp(B) p exp(B) p 
Language 0.742 0.062 0.574 0.021 0.362 <0.001* 0.845 0.522 
Verbal Fluency 0.824 0.146 0.634 0.023 0.795 0.347 0.790 0.284 
Executive functioning 0.965 0.755 0.891 0.504 0.815 0.329 0.878 0.489 
ALS Specific 0.864 0.167 0.739 0.054 0.717 0.093 0.854 0.375 
Memory 0.857 0.130 0.787 0.125 0.779 0.187 0.845 0.325 
Visuospatial 0.804 0.026 0.652 0.004 0.625 0.009 0.812 0.201 
ALS Non-specific 0.820 0.058 0.696 0.018 0.720 0.091 0.799 0.199 
Total ECAS 0.857 0.118 0.725 0.026 0.710 0.061 0.836 0.276 
  OR 95%CI OR 95%CI OR 95%CI OR 95%CI 
Disinhibition 0.352 0.019 to 1.879 <0.001 - <0.001 - <0.001 - 
Apathy or inertia 2.059 0.883 to 4.705 2.248 0.620 to 7.839 5.455 0.027 to 3.698 1.560 -1.172 to 1.891 
Loss of sympathy or empathy 0.858 0.236 to 2.487 0.532 0.028 to 2.967 <0.001 - 1.903 -1.316 to 2.176 
Perseveration 2.026 0.721 to 5.237 1.241 0.182 to 5.195 1.104 -2.876 to 1.979 <0.001 - 
Hyperorality or altered food 
preferences 1.903 0.632 to 5.140 2.606 0.538 to 9.883 1.291 -2.722 to 2.142 -0.909 -3.048 to 1.699 
For MND-FTSD subclass, a family history of any neuropsychiatric disorder was associated 
with an increased risk of MND-FTD and MNDbi versus MND with no impairment. 
Examination of each neuropsychiatric disorder showed that a family history of mood and 
neurotic disorders were associated with an increased risk of MND-FTD versus MND with no 
impairment (Table 7).  
 
The presence of any behaviour impairment was associated with a family history of any 
neuropsychiatric disorders or neurotic disorders (Figure 2b). We did not find any associations 
between family history of neuropsychiatric disorders and the presence of any cognitive 
impairment.
Table 7. Family history of neuropsychiatric disorders and MND-FTD subclass 
 
 
Any neuropsychiatric 
in family history Mood disorder 
Neurotic disorder Schizophrenia, schizotypal 
and delusional disorders 
  OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
MND (ref) - - - - - - - - 
MND-FTD 5.077 1.263 to 20.403 7.571 1.555 to 46.867 13.750 1.705 to 110.861 6.111 0.504 to 74.061 
MNDbi 3.136 1.094 to 8.989 1.606 0.304 to 8.488 5.000 0.668 to 37.418 5.000 0.667 to 37.418 
MNDci 1.202 0.484 to 2.988 0.841 0.203 to 3.482 0.846 0.075 to 9.515 3.548 0.632 to 19.929 
MNDcbi 1.270 0.328 to 4.906 1.860 0.349 to 9.910 5.789 0.768 to 43.623 2.750 0.238 to 31.781 
Results in bold indicate a significant association.  
 
 
DISCUSSION 
We showed that the associations between MND, FTD and neuropsychiatric disorders extend 
into the cognitive and behavioural features in MND. A premorbid mood disorder in an MND 
patient is associated with a 2.78 increase in the odds of apathy post-MND diagnosis and a 
family history of any neuropsychiatric disorder is associated with 3.14 and 5.08 increased 
odds of MNDbi and MND-FTD respectively. More specifically, a family history of mood 
disorder is associated with poorer overall cognition in addition to a 7.57 increase in the odds 
of MND-FTD. Patients with a family history of neurotic disorders are more likely to have 
poorer cognition, including language and visuospatial functioning, and a 13.75 increase in the 
odds of MND-FTD. These associations may contribute to the spectrum of cognitive and 
behavioural changes in MND. 
 
Previous research has suggested that the C9orf72 expansion accounts for some of the shared 
predisposition between MND, FTD and neuropsychiatric disorders. In one study, C9orf72 
was associated with higher rates of schizophrenia, suicide and autism in ALS and FTD family 
members.32 Some studies have also shown an association between C9orf72 and cognition in 
ALS and FTD patients however these findings have been mixed.33, 34 We showed that those 
with and without a personal or family history of neuropsychiatric disorders did not differ on 
C9orf72 status. To our knowledge, we are also the first to show that both patient and family 
neuropsychiatric history is associated with cognitive and behaviour changes in MND, 
independent of the patients C9orf72 status. These findings suggest that although a shared 
predisposition exists, factors other than C9orf72 status are contributing to this susceptibility. 
Furthermore, those with a premorbid neuropsychiatric disorder had a shorter disease duration 
at the time of ECAS assessment. This suggests that a neuropsychiatric history may be 
associated with poor cognition in the earlier stages of the disease however further research is 
needed to confirm this. 
 
We showed associations across both ALS specific and non-specific cognitive domains. 
Although ALS non-specific, including visuospatial impairment, are less common in MND, 
different cognitive profiles exist and other factors may be contributing. Impaired visuospatial 
skills are common in Alzheimer’s Disease (AD)35 therefore our results may reflect the 
presence of mild AD pathology. Alternatively, visuospatial skills have been shown to decline 
with increasing disease stage, even in FTD35 therefore it may be an effect of disease stage.  
 Many associations did appear to be driven by MND-FTD patients and were no longer 
significant after removal of these cases. However, a family history of neurotic disorders and 
language scores remained significant after the removal of MND-FTD cases showing that 
these associations exist in non-demented MND patients. Furthermore, many associations 
were found with MNDbi and more specific cognitive deficits suggesting that 
neuropsychiatric history is associated with the full spectrum of cognitive and behavioural 
changes in MND. Future research using more in-depth measures of neuropsychiatric 
disorders, including subclinical symptoms, may be more sensitive and reveal further 
associations. 
 
We were able to identify cases of premorbid neuropsychiatric disorders in MND patients 
using diagnosis date and found a strong relationship between premorbid mood disorders and 
apathy post-MND diagnosis. These findings suggest that a history of mood disorders may be 
a risk factor for the development of apathy in MND. Apathy or demotivation is the most 
common behavioural impairment in ALS.36, 37 Although some symptoms of depression and 
apathy may overlap, a dissociation in ALS has been demonstrated37 and the distinct profile of 
initiation apathy found in ALS has been related to a cognitive failure to initiate as 
demonstrated by verbal fluency deficits.38 Early signs of apathy may have been captured as 
premorbid mood disorders on the CARE-MND platform. Little is known about timing of 
cognitive and behavioural symptoms relative to motor symptom onset in MND. However, 
these are likely to be mood disorders as only 7/28 (25%) cases were diagnosed with mood 
disorders in the 5 years prior to MND diagnosis.  
 
Associations between neuropsychiatric history and later-life disease have previously been 
demonstrated. An increased risk of dementia has been associated with a history of depression, 
anxiety, bipolar, schizophrenia and alcohol dependence.39 Parkinson’s Disease has also been 
associated with premorbid depression.40 However, few studies have explored how premorbid 
neuropsychiatric disorders relate to cognitive and behavioural changes in neurodegenerative 
disease, including MND. The findings from this study highlight the contribution of 
neuropsychiatric symptoms to the cognitive and behavioural profiles in MND. 
 
Our population-based study includes all MND patients in Scotland with cognitive and/or 
behavioural information assessed using the ECAS. This information allowed us to group 
patients using established cut-offs and the latest ALS-FTSD classifications.3, 20 Rates of 
cognitive and/or behavioural impairment in our sample (156/305, 51.1%) were consistent 
with previous research.1 We identified cases of MND-FTD based on neurologist diagnosis 
therefore they may not be in strict adherence to the ALS-FTSD criteria.3 This may have 
contributed to fewer cases being identified than in previous research; however our rates 
(17/305, 5.57%) were comparable to published frequencies.41 A classification of MND-FTD 
cannot be made using ECAS data available on the CARE-MND platform as information 
indicating progression of cognitive and/or behavioural symptoms, a key criterion, is 
unavailable. Based on the other two MND-FTD criteria3 an additional 23 patients may have 
MND-FTD, however this could not be confirmed. The ECAS is generally administered 
shortly following diagnosis; however changes in cognition and behaviour have been shown to 
increase in the final stages of the disease29 therefore some patients may go on to develop 
MND-FTD.  
 
Neuropsychiatric disorders were uncommon in the MND kindreds included in our study. We 
identified mood disorders in 42 (13.77%) patients and 28 (9.18%) family members which is 
lower than expected based on previous research14, 15 and rates found in the UK Biobank 
(27.20% of 123,000).42 This resulted in small numbers in some analyses therefore these 
results should be interpreted cautiously. We were unable to examine associations with 
psychosis, schizophrenia or autism, neuropsychiatric disorders which have been shown to 
occur at higher rates in MND kindreds.11, 14, 15 The number of patients with neuropsychiatric 
medication was higher than those with a neuropsychiatric history (127 vs 60). Information on 
the duration and reason for neuropsychiatric medication use was not available on the CARE-
MND register. Therefore, cases were neuropsychiatric medication was prescribed to treat 
short-term symptoms not meeting diagnostic criteria or non-neuropsychiatric symptoms (e.g. 
Duloxetine to treat fibromyalgia) may be been included. This may have contributed to the 
lack of associations found.  
 
We used patient-reported family history data which may have contributed to the lower rates 
of neuropsychiatric disorders. The social stigma around mental health may prevent the 
sharing of this information and social and behavioural difficulties may lead to a loss of 
contact with family members. Furthermore 74/305 (24.26%) patients did not have any family 
history information. We may also have missed patient cases of neuropsychiatric disorders as 
we were unable to capture those: with subclinical symptoms not meeting traditional 
diagnostic criteria; without an official diagnosis; who did not seek medical treatment; with 
previously under recognised disorders (i.e. autism spectrum disorders). Future research using 
more comprehensive and complete family and patient data may reveal stronger associations.  
 
C9orf72 status was available for 259 (85%) patients in this study, allowing us to account for 
this in secondary analysis. Although we showed that almost all associations between patient 
and family neuropsychiatric history, and cognition and behaviour remained after controlling 
for the patients C9orf72 status, we did not control for any other factors. Future studies may 
also include other confounding variables and other genes or whole genome sequencing 
previously associated with cognitive and behavioural impairment.41 Furthermore, future 
research should include other patient groups and healthy controls to determine whether these 
associations are specific to MND.  
 
Finally, we focused on results unadjusted for multiple comparisons increasing the risk of a 
false-positive result. This study is experimental and hypothesis generating therefore it is 
important to show unadjusted effects as these warrant further examination in future 
research.43 However, unadjusted findings should be interpreted with caution.  
 
CONCLUSION 
This is the first study to show that neuropsychiatric disorders in patients (premorbidly) and 
their family members are associated with cognitive and behavioural changes in MND. These 
associations were evident in those with premorbid neuropsychiatric disorders, without 
concurrent FTD and remained after accounting for C9orf72 status. These results provide 
further evidence of an overlap between MND, FTD and neuropsychiatric disorders and 
highlight the importance of further, large-scale studies, using more in-depth measurement of 
neuropsychiatric disorders and family history.  
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eTable 1. Neuropsychiatric medications on the register and their class. 
 
Drug Name Class Used to treat 
Fluoxetine SSRI Depression, OCD, bulimia and panic disorders. 
Citalopram SSRI Depression, panic disorder, agoraphobia and OCD. 
Sertraline SSRI Depression, panic attacks, OCD and PTSD. 
Duloxetine SSRI Depression, GAD and fibromyalgia. 
Paroxetine SSRI Depression, OCD, social anxiety, panic disorder, PTSD and GAD. 
Escitalopram SSRI Depression. 
Amitriptyline TCA Depression, anxiety disorders, ADHD and bipolar disorder. 
Clomipramine TCA OCD, panic disorder and depression. 
Imipramine TCA Depression. 
Nortriptyline TCA Depression. 
Venlafaxine SNRI Depression, GAD, panic disorder and social phobia. 
Mirtazapine NaSSA Depression, anxiety and insomnia. 
Trazodone SARI Depression and anxiety. 
Clonazepam  Benzodiazepine Anxiety, seizure disorders and panic disorder. 
Diazepam Benzodiazepine Anxiety and alcohol withdrawal. 
Lorazepam Benzodiazepine Anxiety disorders, insomnia, active seizures and alcohol withdrawal. 
Temazepam Benzodiazepine Anxiety and insomnia. 
Olanzapine Antipsychotic Schizophrenia and bipolar disorder. 
Risperidone Antipsychotic Schizophrenia, bipolar disorder and irritability in people with Autism. 
Quetiapine Antipsychotic Schizophrenia, bipolar disorder and Depression. 
Lithium Anti-manic Depression and bipolar disorder.  
Naltrexone   Alcohol dependence and opioid dependence. 
SSRI=Selective serotonin reuptake inhibitors; TCA=Tricyclic anti-depressant; 
SNRI=Serotonin and norepinephrine reuptake inhibitors; NaSSA=Noradrenergic and specific 
serotonergic antidepressant; SARI=Serotonin antagonist and reuptake inhibitors; 
OCD=Obsessive-Compulsive Disorder; PTSD=Post-traumatic stress disorder; 
GAD=Generalised anxiety disorder; ADHD=Attention deficit hyperactivity disorder.
eTable 2. Premorbid depression and anxiety associations with ECAS cognitive and behaviour scores. 
 
 Premorbid Neuropsychiatric Disorders Only (n=39) 
 
Any neuropsychiatric 
disorder Mood Disorder Neurotic Disorder 
  exp(B) p exp(B) p exp(B) p 
Language 0.882 0.373 0.777 0.123 1.095 0.699 
Verbal Fluency 0.916 0.480 0.904 0.491 0.883 0.563 
Executive functioning 0.905 0.346 0.908 0.434 1.116 0.544 
ALS Specific 0.903 0.320 0.893 0.346 1.075 0.681 
Memory 0.889 0.201 0.841 0.109 0.905 0.530 
Visuospatial 0.976 0.798 0.939 0.559 1.146 0.381 
ALS Non-specific 0.902 0.275 0.852 0.147 0.959 0.798 
Total ECAS 0.901 0.256 0.879 0.233 1.038 0.815 
Total number of behaviour domains 1.180 0.167 1.163 0.264 0.984 0.941 
  OR 95%CI OR 95%CI OR  95%CI 
Disinhibition 1.153 0.257 to 3.729 0.961 0.146 to 3.676 <0.001 - 
Apathy or inertia 2.009 0.848 to 4.647 2.784 1.083 to 7.169 1.914 0.368 to 8.937 
Loss of sympathy or empathy 0.732 0.205 to 2.057 0.715 0.161 to 2.267 0.687 0.036 to 4.181 
Perseveration 1.344 0.422 to 3.624 1.405 0.382 to 4.161 0.901 0.047 to 5.521 
Hyperorality or altered food preferences 0.683 0.155 to 2.124 0.959 0.215 to 3.079 0.906 0.047 to 5.553 
Results in bold indicate a significant association.
eFigure 1. Risk of any cognitive (MNDci, MNDcbi or MND-FTD) or behavioural (MNDbi, MNDcbi or MND-FTD) impairment – Premorbid 
cases. 
 
a) Premorbid Patient Neuropsychiatric Disorders 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) Premorbid Patient Neuropsychiatric Medication 
 
 
 
 
 
 
 
 
 
 
 
 
 
eTable 3. Premorbid patient neuropsychiatric disorders and MND-FTSD subclasses. 
 
 Premorbid Neuropsychiatric disorders only (n=39) 
 
Any premorbid 
neuropsychiatric Mood Disorder Neurotic Disorder 
  OR 95% CI OR 95% CI OR 95% CI 
MND (ref) - - - - - - 
MND-FTD 1.148 0.237 to 5.555 2.200 0.431 to 11.219 1.744 0.195 to 15.613 
MNDbi 1.498 0.505 to 4.437 2.870 0.898 to 9.165 0.840 0.097 to 7.257 
MNDci 0.827 0.226 to 3.020 1.015 0.210 to 4.907 1.333 0.364 to 4.884 
MNDcbi 1.242 0.552 to 2.793 1.886 0.730 to 4.872 0.840 0.097 to 7.257 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eTable 4. Patient neuropsychiatric medication associations with ECAS cognitive and behavioural scores. 
 
 Any neuropsychiatric medication (n=127) 
 
Any neuropsychiatric 
disorder Anti-depressants Benzodiazepines Anti-psychotics 
  exp(B) p exp(B) p exp(B) p exp(B) p 
Language 0.889 0.225 0.935 0.529 1.086 0.515 0.578 0.133 
Verbal Fluency 0.921 0.334 0.928 0.417 1.171 0.153 0.887 0.707 
Executive functioning 1.022 0.767 1.025 0.750 1.039 0.687 0.741 0.265 
ALS Specific 0.975 0.717 0.981 0.805 1.088 0.354 0.749 0.273 
Memory 0.982 0.772 0.988 0.860 1.032 0.692 0.660 0.070 
Visuospatial 0.939 0.331 0.979 0.758 0.963 0.657 1.355 0.209 
ALS Non-specific 0.980 0.755 0.998 0.974 1.043 0.613 0.699 0.131 
Total ECAS 0.980 0.748 0.987 0.843 1.096 0.262 0.719 0.163 
  OR 95%CI OR 95%CI OR  95%CI OR  95%CI 
Disinhibition 0.868 0.364 to 1.980 0.541 0.175 to 1.399 0.532 0.122 to 1.626 2.667 0.129 to 21.744 
Apathy or inertia 0.901 0.502 to 1.599 1.233 0.661 to 2.265 0.480 0.197 to 1.051 7.385 0.927 to 150.789 
Loss of sympathy or empathy 1.071 0.554 to 2.045 0.923 0.439 to 1.853 0.570 0.205 to 1.356 3.978 0.467 to 33.891 
Perseveration 0.891 0.422 to 1.831 1.278 0.581 to 2.693 0.654 0.212 to 1.663 5.588 0.653 to 47.875 
Hyperorality or altered food 
preferences 0.834 0.397 to 1.703 0.877 0.382 to 1.880 0.633 0.206 to 1.608 1.750 0.085 to 14.105 
eTable 5. Patient neuropsychiatric medication and MND-FTSD subclass. 
 
 Neuropsychiatric medication at any time point (n=127) 
 
Any neuropsychiatric 
medication Anti-depressants Benzodiazepines Anti-psychotics 
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
MND (ref) - - - - - - - - 
MND-FTD 1.130 0.407 to 3.136 1.538 0.533 to 4.439 <0.001 - 9.250 0.552 to 155.091 
MNDbi 1.519 0.712 to 3.243 1.833 0.834 to 4.032 0.680 0.242 to 1.905 4.625 0.282 to 75.906 
MNDci 1.417 0.812 to 2.472 1.356 0.744 to 2.473 0.921 0.462 to 1.834 1.947 0.120 to 31.565 
MNDcbi 0.986 0.435 to 2.239 1.269 0.533 to 3.022 0.439 0.125 to 1.547 5.286 0.321 to 87.016 
 
 
 
eFigure 2 Risk of any cognitive (MNDci, MNDcbi or MND-FTD) or behavioural (MNDbi, MNDcbi or MND-FTD) impairment by patient 
neuropsychiatric medication for all identified cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eTable 6. Patient premorbid neuropsychiatric medication associations with ECAS cognitive and behavioural scores. 
 
 Premorbid neuropsychiatric medication only (n=25) 
 
Any neuropsychiatric 
disorder Anti-depressants Benzodiazepines Anti-psychotics 
  exp(B) p exp(B) p exp(B) p exp(B) p 
Language 0.859 0.382 0.849 0.358 0.735 0.241 0.545 0.432 
Verbal Fluency 1.083 0.622 1.041 0.808 1.298 0.282 1.336 0.684 
Executive functioning 1.073 0.591 1.003 0.514 0.970 0.878 0.770 0.653 
ALS Specific 0.955 0.726 0.958 0.746 0.982 0.925 1.135 0.827 
Memory 0.989 0.926 0.953 0.683 0.834 0.293 0.527 0.206 
Visuospatial 1.055 0.646 1.042 0.728 0.928 0.670 1.308 0.601 
ALS Non-specific 1.000 0.999 0.961 0.743 0.845 0.346 0.557 0.263 
Total ECAS 1.017 0.875 1.003 0.981 0.976 0.879 0.771 0.584 
  OR 95%CI OR 95%CI OR  95%CI OR  95%CI 
Disinhibition <0.001 - <0.001 - <0.001 - <0.001 - 
Apathy or inertia 0.810 0.249 to 2.275 0.882 0.269 to 2.508 0.765 0.109 to 3.472 <0.001 - 
Loss of sympathy or empathy 0.466 0.071 to 1.763 0.500 0.076 to 1.903 1.457 0.206 to 6.730 <0.001 - 
Perseveration 0.283 0.015 to 1.485 0.302 0.016 to 1.594 0.799 0.042 to 4.809 <0.001 - 
Hyperorality or altered food preferences 0.268 0.015 to 1.404 0.286 0.016 to 1.507 0.758 0.040 to 4.551 <0.001 - 
 
 
 
 
 
 
 
 
 
eTable 7. Patient premorbid neuropsychiatric medication and MND-FTSD subclass. 
 
 Premorbid Neuropsychiatric medication only (n=25) 
 
Any premorbid 
neuropsychiatric 
medication 
Anti-depressants Benzodiazepines Anti-psychotics 
  OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
MND (ref) - - - - - - - - 
MND-FTD <0.001 - <0.001 - <0.001 - <0.001 - 
MNDbi 1.082 0.282 to 4.147 1.172 0.304 to 4.521 0.886 0.101 to 7.783 <0.001 - 
MNDci 0.598 0.187 to 1.914 0.648 0.201 to 2.089 0.383 0.045 to 3.273 <0.001 - 
MNDcbi 1.022 0.268 to 3.898 1.107 0.289 to 4.250 1.772 0.332 to 9.447 <0.001 - 
 
 
 
 
 
 
 
 
